Investors remain optimistic about Patterson Companies on the back of its broad product line.
Vous n'êtes pas connecté
Investors remain optimistic about QGEN due to its progress in test menu expansion and impressive prospects within its molecular diagnostics segments.
Investors remain optimistic about Patterson Companies on the back of its broad product line.
Investors remain optimistic about Patterson Companies on the back of its broad product line.
STE's strong prospects in the healthcare business arm bode well for investors.
RVTY's strong product portfolio raises optimism about the stock.
To support internal growth, QIAGEN invests heavily in research and development for the menu expansion of its key platforms.
NARI continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.
PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.
Omnicell is well-placed for growth in the upcoming quarters owing to its progress in achieving the Autonomous Pharmacy goal.
NWN makes a strong case for investment, given its growth prospects, better debt management and capability to increase shareholders' value.
NWN makes a strong case for investment, given its growth prospects, better debt management and capability to increase shareholders' value.